147 related articles for article (PubMed ID: 27084277)
1. Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study.
Haslett K; Franks K; Hanna GG; Harden S; Hatton M; Harrow S; McDonald F; Ashcroft L; Falk S; Groom N; Harris C; McCloskey P; Whitehurst P; Bayman N; Faivre-Finn C
BMJ Open; 2016 Apr; 6(4):e010457. PubMed ID: 27084277
[TBL] [Abstract][Full Text] [Related]
2. Accelerated, Dose escalated, Sequential Chemoradiotherapy in Non-small-cell lung cancer (ADSCaN): a protocol for a randomised phase II study.
Hatton MQF; Lawless CA; Faivre-Finn C; Landau D; Lester JF; Fenwick J; Simões R; McCartney E; Boyd KA; Haswell T; Shaw A; Paul J
BMJ Open; 2019 Jan; 9(1):e019903. PubMed ID: 30700475
[TBL] [Abstract][Full Text] [Related]
3. Isotoxic Intensity Modulated Radiation Therapy in Stage III Non-Small Cell Lung Cancer: A Feasibility Study.
Haslett K; Bayman N; Franks K; Groom N; Harden SV; Harris C; Hanna G; Harrow S; Hatton M; McCloskey P; McDonald F; Ryder WD; Faivre-Finn C
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1341-1348. PubMed ID: 33232772
[TBL] [Abstract][Full Text] [Related]
4. Study protocol: a multicentre, prospective, phase II trial of isotoxic hypofractionated concurrent chemoradiotherapy for non-small cell lung cancer.
Liu YE; Xue XY; Zhang R; Chen XJ; Ding YX; Liu CX; Qin YL; Li WQ; Ren XC; Lin Q
BMJ Open; 2020 Oct; 10(10):e036295. PubMed ID: 33099491
[TBL] [Abstract][Full Text] [Related]
5. Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status.
Faivre-Finn C; Falk S; Ashcroft L; Bewley M; Lorigan P; Wilson E; Groom N; Snee M; Fournel P; Cardenal F; Bezjak A; Blackhall F
BMJ Open; 2016 Jan; 6(1):e009849. PubMed ID: 26792218
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study.
Jeter MD; Gomez D; Nguyen QN; Komaki R; Zhang X; Zhu X; O'Reilly M; Fossella FV; Xu T; Wei X; Wang H; Yang W; Tsao A; Mohan R; Liao Z
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):730-737. PubMed ID: 29248169
[TBL] [Abstract][Full Text] [Related]
7. An isotoxic planning comparison study for stage II-III non-small cell lung cancer: is intensity-modulated radiotherapy the answer?
Warren M; Webster G; Ryder D; Rowbottom C; Faivre-Finn C
Clin Oncol (R Coll Radiol); 2014 Aug; 26(8):461-7. PubMed ID: 24793504
[TBL] [Abstract][Full Text] [Related]
8. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
9. Dose-escalation by hypofractionated simultaneous integrated boost IMRT in unresectable stage III non-small-cell lung cancer.
Zhang Q; Cai XW; Feng W; Yu W; Fu XL
BMC Cancer; 2022 Jan; 22(1):96. PubMed ID: 35065627
[TBL] [Abstract][Full Text] [Related]
10. Individualized accelerated isotoxic concurrent chemo-radiotherapy for stage III non-small cell lung cancer: 5-Year results of a prospective study.
De Ruysscher D; van Baardwijk A; Wanders R; Hendriks LE; Reymen B; van Empt W; Öllers MC; Bootsma G; Pitz C; van Eijsden L; Dingemans AC
Radiother Oncol; 2019 Jun; 135():141-146. PubMed ID: 31015160
[TBL] [Abstract][Full Text] [Related]
11. Concurrent chemoradiotherapy with weekly nedaplatin versus radiotherapy alone in elderly patients with non-small-cell lung cancer.
Chen F; Hu P; Liang N; Xie J; Yu S; Tian T; Zhang J; Deng G; Zhang J
Clin Transl Oncol; 2018 Mar; 20(3):294-301. PubMed ID: 28741074
[TBL] [Abstract][Full Text] [Related]
12. Chemoradiotherapy by intensity-modulated radiation therapy with simultaneous integrated boost in locally advanced or oligometastatic non-small-cell lung cancer-a two center experience.
Mantel F; Müller E; Kleine P; Zimmermann M; Exner F; Richter A; Weick S; Ströhle S; Polat B; Höcht S; Flentje M
Strahlenther Onkol; 2021 May; 197(5):405-415. PubMed ID: 33725133
[TBL] [Abstract][Full Text] [Related]
13. Dose-escalated Hypofractionated Intensity-modulated Radiation Therapy With Concurrent Chemotherapy for Inoperable or Unresectable Non-Small Cell Lung Cancer.
Kim JO; Chu KP; Fairchild A; Ghosh S; Butts C; Chu Q; Gabos Z; Joy AA; Nijjar T; Robinson DM; Sangha R; Scrimger R; Smylie M; Yee D; Roa WH
Am J Clin Oncol; 2017 Jun; 40(3):294-299. PubMed ID: 25333733
[TBL] [Abstract][Full Text] [Related]
14. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.
Chun SG; Hu C; Choy H; Komaki RU; Timmerman RD; Schild SE; Bogart JA; Dobelbower MC; Bosch W; Galvin JM; Kavadi VS; Narayan S; Iyengar P; Robinson CG; Wynn RB; Raben A; Augspurger ME; MacRae RM; Paulus R; Bradley JD
J Clin Oncol; 2017 Jan; 35(1):56-62. PubMed ID: 28034064
[TBL] [Abstract][Full Text] [Related]
15. Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: Analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary cancer center.
Shrimali RK; Nallathambi C; Saha A; Das A; Prasath S; Mahata A; Arun B; Mallick I; Achari R; Dabkara D; Thambudorai R; Chatterjee S
Indian J Cancer; 2018; 55(2):125-133. PubMed ID: 30604722
[TBL] [Abstract][Full Text] [Related]
16. SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status.
Maguire J; Khan I; McMenemin R; O'Rourke N; McNee S; Kelly V; Peedell C; Snee M
Eur J Cancer; 2014 Nov; 50(17):2939-49. PubMed ID: 25304298
[TBL] [Abstract][Full Text] [Related]
17. High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study.
Liu YE; Lin Q; Meng FJ; Chen XJ; Ren XC; Cao B; Wang N; Zong J; Peng Y; Ku YJ; Chen Y
Radiat Oncol; 2013 Aug; 8(1):198. PubMed ID: 23937855
[TBL] [Abstract][Full Text] [Related]
18. Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy.
Koshy M; Malik R; Spiotto M; Mahmood U; Rusthoven CG; Sher DJ
Lung Cancer; 2017 Jun; 108():222-227. PubMed ID: 28625640
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of intensity modulated radiotherapy with involved field radiotherapy for Japanese patients with locally advanced non-small cell lung cancer.
Abe T; Iino M; Saito S; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki Y; Miura Y; Kaira K; Kagamu H; Noda SE; Kato S
J Radiat Res; 2021 Sep; 62(5):894-900. PubMed ID: 34260719
[TBL] [Abstract][Full Text] [Related]
20. [A Phase I/II Study of Chemotherapy Concurrent with Twice-daily Radiotherapy
Schedules by Intensity Modulated Radiation Therapy Using Simultaneous Integrated Boost for Limited-stage Small Cell Lung Cancer].
You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):28-34. PubMed ID: 28103970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
